DE3377363D1 - Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells - Google Patents

Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells

Info

Publication number
DE3377363D1
DE3377363D1 DE8383101035T DE3377363T DE3377363D1 DE 3377363 D1 DE3377363 D1 DE 3377363D1 DE 8383101035 T DE8383101035 T DE 8383101035T DE 3377363 T DE3377363 T DE 3377363T DE 3377363 D1 DE3377363 D1 DE 3377363D1
Authority
DE
Germany
Prior art keywords
recombinant dna
interleukin
gene
polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383101035T
Other languages
English (en)
Inventor
Tadatsugu Taniguchi
Masami Muramatsu
Haruo Sugano
Hiroshi Matsui
Nobukazu Kashima
Junji Hamuro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Japanese Foundation for Cancer Research
Original Assignee
Ajinomoto Co Inc
Japanese Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27550424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3377363(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP57051122A external-priority patent/JPS58170798A/ja
Priority claimed from JP57082509A external-priority patent/JPS58201979A/ja
Priority claimed from JP57219518A external-priority patent/JPS59140878A/ja
Priority claimed from JP57229619A external-priority patent/JPS59140882A/ja
Priority claimed from JP57234607A external-priority patent/JPS59140898A/ja
Priority claimed from JP57230371A external-priority patent/JPS59140897A/ja
Application filed by Ajinomoto Co Inc, Japanese Foundation for Cancer Research filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of DE3377363D1 publication Critical patent/DE3377363D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
DE8383101035T 1982-03-31 1983-02-03 Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells Expired DE3377363D1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP57051122A JPS58170798A (ja) 1982-03-31 1982-03-31 メツセンジヤ−ｒｎａおよびその調製法
JP57082509A JPS58201979A (ja) 1982-05-18 1982-05-18 ヒトインタ−ロイキン２遺伝子が組込まれているエシエリヒア・コリおよびその育種方法
JP57219518A JPS59140878A (ja) 1982-12-15 1982-12-15 組換え体微生物
JP57229619A JPS59140882A (ja) 1982-12-24 1982-12-24 インターロイキン２活性をもつポリペプチドをコードする遺伝子
JP57234607A JPS59140898A (ja) 1982-12-27 1982-12-27 インタ−ロイキン−２の製造法
JP57230371A JPS59140897A (ja) 1982-12-29 1982-12-29 インタ−ロイキン−２の製造方法

Publications (1)

Publication Number Publication Date
DE3377363D1 true DE3377363D1 (en) 1988-08-18

Family

ID=27550424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8383101035T Expired DE3377363D1 (en) 1982-03-31 1983-02-03 Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells

Country Status (3)

Country Link
US (6) US4738927A (de)
EP (1) EP0091539B2 (de)
DE (1) DE3377363D1 (de)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663285A (en) * 1981-01-06 1987-05-05 The Public Health Laboratory Service Board Chimeric plasmids
JPS58116498A (ja) * 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
EP0091539B2 (de) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
EP0121569B1 (de) * 1982-10-08 1990-08-22 Kyowa Hakko Kogyo Co., Ltd. Neuer vektor
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5700913A (en) * 1982-12-15 1997-12-23 Ajinomoto Co., Inc. Unglycosylated human interleukin-2 polypeptides
AU579089B2 (en) * 1983-02-08 1988-11-17 Biogen, Inc. Human interleukin-2-like polypeptides
IL71275A0 (en) * 1983-03-21 1984-06-29 Sparamedica Ag Human interleukin-2-and its preparation
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
GB8327880D0 (en) * 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
WO1985002200A1 (en) * 1983-11-14 1985-05-23 Chiron Corporation Interleukin-2 production using cloned genes for interleukin-2 and yeast alpha-factor
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
DK174501B1 (da) * 1983-12-23 2003-04-28 Hoffmann La Roche Fremgangsmåde til fremstilling af interleukin-2
FR2559782B1 (fr) * 1984-02-16 1986-07-18 Transgene Sa Vecteur d'expression dans les levures de l'interleukine-2, levures transformees et procede de preparation de l'interleukine-2
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
WO1985004328A1 (en) 1984-03-28 1985-10-10 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0158198A1 (de) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA und ihre Verwendung
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
EP0163603B1 (de) * 1984-05-08 1989-12-13 Genetics Institute, Inc. Ein menschlicher T-Zellwachstumsfaktor
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
EP0172619A1 (de) * 1984-06-20 1986-02-26 Takeda Chemical Industries, Ltd. Transformand und dessen Verwendung
JPS6156078A (ja) * 1984-07-27 1986-03-20 Suntory Ltd 酵母を宿主とする分泌発現ベクタ−
PT79506B (en) * 1984-08-08 1986-09-08 Quidel T-cell growth factor
WO1986002068A1 (en) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Mutual separation of proteins
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
EP0177357A1 (de) * 1984-10-05 1986-04-09 Schering Biotech Corporation cDNA-Klone, die für Polypeptide kodieren, die Murin-Interleukin-2-Aktivität zeigen
US5317087A (en) * 1984-11-13 1994-05-31 Immunex Corporation Purification of the IL-2 receptor
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JPH0646957B2 (ja) * 1985-03-11 1994-06-22 武田薬品工業株式会社 インタ−ロイキン−２の製造方法
JPS61225199A (ja) * 1985-03-29 1986-10-06 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−ロイキン２ポリペチド誘導体
FR2583770B1 (fr) * 1985-06-21 1988-08-19 Transgene Sa Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5496924A (en) * 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4992367A (en) * 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US4939093A (en) * 1987-02-02 1990-07-03 Cetus Corporation Human IL-2 like polypeptides, DNA sequences and recombinant DNA molecules therefore and methods for the production and use thereof
US5162503A (en) * 1987-05-19 1992-11-10 Hoffmann-La Roche, Inc. Purification of interleukin-2 by receptor-affinity chromatography
US5149788A (en) * 1987-05-19 1992-09-22 Hoffmann-La Roche, Inc. Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5152980A (en) * 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6899882B1 (en) * 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DK455789D0 (da) * 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
WO1991005052A1 (en) * 1989-09-28 1991-04-18 Leningradsky Gosudarstvenny Universitet Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae
DK0500799T3 (da) * 1989-11-16 1998-09-14 Univ Duke Partikel-medieret transformation af animalske vævsceller
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5449691A (en) * 1991-12-31 1995-09-12 Sterling Winthrop Inc. 3,4-disubstituted anilines-immunomodulating agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
WO1994018995A1 (en) * 1993-02-17 1994-09-01 Sloan-Kettering Institute For Cancer Research Allogeneic vaccine and method to synthesize same
ATE215989T1 (de) 1993-09-15 2002-04-15 Chiron Corp Rekombinanter alphavirus vektor
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
DK0938320T3 (da) * 1996-03-26 2010-10-18 Michael S Kopreski Metode til at ud af plasma eller serum tilvejebringe ekstraheret ekstracellulært RNA for at detektere, overvåge eller vurdere cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
EP1997900A3 (de) 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Rekombinante Vektoren auf Alphavirus-Basis mit reduzierter Hemmung der zellulären Makromolekularsynthese
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6008319A (en) * 1996-12-23 1999-12-28 University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6306589B1 (en) * 1998-05-27 2001-10-23 Vysis, Inc. Biological assays for analyte detection
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7662368B2 (en) * 1999-07-16 2010-02-16 Institut Pasteur Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US7364750B2 (en) * 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP2280074A3 (de) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
EP1419236A4 (de) * 2001-07-24 2005-08-03 Biogen Idec Inc Verfahren zur behandlung von sklerotischen erkrankungen unter verwendung cd2-bindender substanzen
ES2367280T3 (es) * 2001-07-25 2011-11-02 Oncomedx Inc. Métodos para evaluar estados patológicos usando arn extracelular.
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
AU2003228751A1 (en) 2002-05-01 2003-11-17 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
PL1682178T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby terapii nowotworów wykazujących ekspresje antygenu CD40
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
WO2005115436A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
EP1814583A2 (de) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Kombinationswege zur erzeugung von immunantworten
WO2006089267A2 (en) * 2005-02-18 2006-08-24 Synthasome Inc. Synthetic structure for soft tissue repair
WO2007019646A1 (en) * 2005-08-19 2007-02-22 University Of Technology, Sydney Liver-directed gene therapy
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US20090155838A1 (en) * 2007-11-28 2009-06-18 Smart Tube, Inc. Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
EP2248903A1 (de) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
US10119959B2 (en) * 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
CN103562390B (zh) 2011-06-01 2017-07-18 英特瑞克斯顿阿克图比奥帝克斯有限公司 用于细菌的多顺反子表达系统
EP3939996A1 (de) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
EP2812012A1 (de) 2012-02-07 2014-12-17 Global Bio Therapeutics USA, Inc. Unterteiltes verfahren zur nucleinsäurefreisetzung sowie zusammensetzungen dafür und verwendungen davon
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
EP3030163B1 (de) 2013-08-08 2019-03-20 Global Bio Therapeutics, Inc. Klemmvorrichtung für minimal-invasive eingriffe
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP2940128A1 (de) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus mit einem albuminbindenden Teil
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
AU2017208153B2 (en) 2016-01-14 2021-01-28 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
MX2019004499A (es) 2016-10-17 2019-11-18 Janssen Pharmaceuticals Inc Star Sistemas de replicón de virus recombinante y usos de estos.
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
JP2021511318A (ja) 2018-01-19 2021-05-06 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
US20220340621A1 (en) 2019-09-27 2022-10-27 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2441659A1 (fr) * 1978-11-14 1980-06-13 Anvar Nouveaux plasmides hybrides et microorganismes les contenant
US4443539A (en) * 1980-02-05 1984-04-17 The Upjohn Company Process for preparing bovine growth hormone
US4430428A (en) * 1980-02-05 1984-02-07 The Upjohn Company Composition of matter and process
US4411992A (en) * 1981-04-14 1983-10-25 Immunex Corporation Process for preparing murine interleukin 2
US4407945A (en) * 1981-04-29 1983-10-04 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4568640A (en) * 1981-05-11 1986-02-04 Harvey Rubin Method of inserting amino acid analogs into proteins
JPS58116498A (ja) * 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
EP0091539B2 (de) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen
US4778879A (en) * 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2

Also Published As

Publication number Publication date
US5795777A (en) 1998-08-18
EP0091539A1 (de) 1983-10-19
US4738927A (en) 1988-04-19
US5399669A (en) 1995-03-21
EP0091539B1 (de) 1988-07-13
US20010041362A1 (en) 2001-11-15
US5795769A (en) 1998-08-18
US5620868A (en) 1997-04-15
EP0091539B2 (de) 1996-11-27

Similar Documents

Publication Publication Date Title
DE3377363D1 (en) Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
ATA392082A (de) Verfahren und vorrichtung zum handhaben von gegenstaenden mittels kontinuierlich bewegter arbeitsmittel
PT73768A (en) Process for stabilizing and selecting host cells with recombinant dna
EP0140973A4 (de) Luftdepolarisierte elektrode und verfahren zur herstellung ihrer katalysators.
IL70573A0 (en) Cell lines,their production and their use for producing proteins
EP0195088A4 (de) Vorrichtung zum trennen von zellen.
DE3463510D1 (en) (21-leucine) human urogastrone, corresponding gene, corresponding recombinant plasmid, transformed cell and process for production thereof
EP0131624A4 (de) Plasmide zur transformation von pflanzenzellen.
IL67503A (en) Messenger rna coding for interleukin-2,production thereof and use thereof in interleukin-2 production
AU581264B2 (en) Electrode for electrochemical processes,method for preparing the same and use thereof in electrolysis cells
AU6605781A (en) Recombinant dna for producing interferon
AU567215B2 (en) Replacing electrolyte lost from cell in reactant gas
PT75643B (en) Method for preparing dna,recombinant dna hosts containing them and polipeptides
AU577156B2 (en) Method and tunnel type furnace for calcining carbonaceous bodies, in particular electrodes
IL70856A0 (en) Dna sequences,recombinant dna molecules and processes for producing human interleukin two-like polypeptides
ZA838277B (en) Porcine growth hormone produced by recombinant dna technology
EP0157385A3 (en) Fuel cell electrode, process for producing the same and fuel cell using the same
AU5907586A (en) Electrochemical cell component, process for preparing same and processes utilising the component
GR3033769T3 (en) Human interferon beta2A, vectors containing genes coding for said interferon, cell lines producing same.
GB2182043A (en) Precursor polypeptide dna sequence coding therefor, vectors, host organisms and processes involving same
IL92685A0 (en) Dna encoding lymphokine/cytokine like proteins,cells transformed thereby and production of said proteins and antibodies against them
EP0170266A3 (en) Process for producing protein, and vector, recombinant dna and transformant used therefor
AU5945386A (en) Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
DE3480311D1 (en) Fuel cell electrolyte matrix and method for manufacturing the same
EP0166445A3 (en) Reinforced zirconia-base sintered body, process for producing the same, and plate-like zirconia-base electrolyte function element

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: STREHL, P., DIPL.-ING. DIPL.-WIRTSCH.-ING. SCHUEBEL-HOPF, U., DIPL.-CHEM. DR.RER.NAT. GROENING, H., DIPL.-ING., PAT.-ANWAELTE, 8000 MUENCHEN

8366 Restricted maintained after opposition proceedings